Joint syndrome in inflammatory bowel diseases
https://doi.org/10.31146/1682-8658-ecg-198-2-131-138
Abstract
The article represents articular extraintestinal manifestations in inflammatory bowel diseases. Joint damage is the most common extraintestinal manifestation in Crohn’s disease and ulcerative colitis and are in the focus of attention of gastroenterologists and rheumatologists. The spectrum of clinical situations accompanied by the development of joint involvement includes peripheral and axial arthropathy, arthropathy with concomitant immunoinflammatory diseases and joint lesions as therapy’s adverse effect. So it requires a differentiated approach to the tactics of patient management. The article describes the main clinical and differential diagnostic features of atropathy in inflammatory bowel diseases and main approaches to therapy. In this context, the article presents the possibilities of using ustekinumab - one of the most effective drugs of biological therapy, the point of application of which is the common subunit p40 of cytokines IL-12 and IL-23. Clinical situations in which the use of this drug is the most effective are described.
About the Authors
Yu. P. Uspenskiy
Saint-Petersburg State Pediatric Medical University; Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
S. V. Ivanov
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
Yu. A. Fominikh
Saint-Petersburg State Pediatric Medical University; Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
Z. Kh. Gulunov
Saint-Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
References
1. Kaser A., Zeissig S., Blumberg R. S. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621. doi: 10.1146/annurev-immunol-030409-101225
2. Ivashkin V.T., Shelygin Yu.A., Belousova E. A., et al. Project of clinical recommendations for the diagnosis and treatment of ulcerative colitis. Coloproctology. 2019;18(4):7-36. (in Russ.) doi: 10.33878/2073-7556-2019-18-4-7-36@@ Ивашкин В. Т., Шелыгин Ю. А., Белоусова Е. А. и соавт. Проект клинических рекомендаций по диагностике и лечению язвенного колита. Колопроктология. 2019;18(4):7-36. doi: 10.33878/2073-7556-2019-18-4-7-36
3. Ivashkin V.T., Shelygin Y. A., Abdulganieva D. I., et al. Clinical recommendations for the diagnosis and treatment of Crohn’s disease in adults (project). Coloproctology. 2020;19(2):8-38. (in Russ.) doi: 10.33878/2073-7556-2020-19-2-8-38@@ Ивашкин В. Т., Шелыгин Ю. А., Абдулганиева Д. И. и соавт. Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект). Колопроктология. 2020;19(2):8-38. doi: 10.33878/2073-7556-2020-19-2-8-38
4. Ng S.C., Shi H. Y., Hamidi N., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0
5. Kappelman M.D., Rifas-Shiman S.L., Kleinman K., et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424-1429. doi: 10.1016/j.cgh.2007.07.012
6. Loftus E. V. The burden of inflammatory bowel disease in the United States: a moving target? Clin Gastroenterol Hepatol. 2007;5:1383-1384. doi: 10.1016/j.cgh.2007.10.016
7. Peery A.F., Crocket S. D., Murphy C. C., et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2018;156(1):254-272. doi: 10.1053/j.gastro.2018.08.063
8. Veselov A.V., Belousova E. A., Bakulin I. G., et al. Economic burden and current status of the drug supply management for immune inflammatory diseases (by example of ulcerative colitis and Crohn’s disease) in Russian Federation. Problems of social hygiene, health care and history of medicine. 2020;28(S2):1137-1145. (in Russ.) doi: 10.32687/0869-866X-2020-28-s2-1137-1145@@ Веселов А. В., Белоусова Е. А., Бакулин И. Г. и соавт. Оценка экономического бремени и текущего состояния организации лекарственного обеспечения пациентов с иммуновоспалительными заболеваниями (на примере язвенного колита и болезни Крона) в Российской Федерации. Проблемы социальной гигиены, здравоохранения и истории медицины. 2020;28(S2):1137-1145. doi: 10.32687/0869-866X-2020-28-s2-1137-1145
9. Khalif I.L., Shapina M. V. Inflammatory bowel disease treatment in Eastern Europe: current status, challenges and needs. Curr Opin Gastroenterol. 2017;33(4):230-233. doi: 10.1097/MOG.0000000000000370
10. Binnatli S.A., Aleshin D. V., Kulikov A. E., Romanov R. I. Quality life of patients operated for ulcerative colitis. Koloproktologia. 2019;18(1(67)):89-100. (in Russ.) doi: 10.33878/2073-7556-2019-18-1-89-100@@ Биннатли Ш. А., Алешин Д. В., Куликов А. Э., Романов Р. И. Качество жизни пациентов, оперированных по поводу язвенного колита (обзор литературы). Колопроктология. 2019;18(1(67)):89-100. doi: 10.33878/2073-7556-2019-18-1-89-100
11. Belousova E.A., Abdulganiyeva D. I., Alexeyeva O. P., et al. Social-demographic characteristics, current features and treatment options for inflammatory bowel diseases in Russia. The results of two multicenter studies. Almanac of Clinical Medicine. 2018;46(5):445-463. (in Russ.) doi: 10.18786/2072-0505-2018-46-5-445-463@@ Белоусова Е. А., Абдулганиева Д. И., Алексеева О. П. и др. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5):445-463. doi: 10.18786/2072-0505-2018-46-5-445-463
12. Uspenskiy Yu.P., Ivanov S. V., Fominikh Yu.A., Galagudza M. M. Features of inflammatory bowel diseases in St. Petersburg and peculiarities of basic therapy in the regional healthcare system: cross- sectional study results. Experimental and Clinical Gastroenterology. 2021;190(6): 29-39. (in Russ.) doi: 10.31146/1682-8658-ecg-190-6-29-39@@ Успенский Ю. П., Иванов С. В., Фоминых Ю. А., Галагудза М. М. Клиническая характеристика воспалительных заболеваний кишечника в Санкт-Петербурге и особенности использования базисной терапии в системе городского здравоохранения: результаты одномоментного эпидемиологического исследования. Экспериментальная и клиническая гастроэнтерология. 2021;190(6): 29-39. doi: 10.31146/1682-8658-ecg-190-6-29-39
13. Harbord M., Annese V., Vavricka S. R., et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(3):239-54. doi: 10.1093/ecco-jcc/jjv213
14. Vavricka S.R., Brun L., Ballabeni P., et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110-119. doi: 10.1038/ajg.2010.343
15. Das K. M. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci. 1999;44(1):1-13. doi: 10.1023/a:1026629528233
16. Monsén U., Sorstad J., Hellers G., Johansson C. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol. 1990;85(6):711-716.
17. Ott C., Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:585-595. doi: 10.1038/nrgastro.2013.117
18. Vavricka S.R., Schoepfer A., Scharl M., et al. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21(8):1982-1992. doi: 10.1097/MIB.0000000000000392
19. Trikudanathan G., Venkatesh P. G., Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012;72(18):2333-2349. doi: 10.2165/11638120-000000000-00000
20. Uspenskiy Y.P., Fominykh. Y.A., Gnutov A. A. Oral lesions in inflammatory bowel diseases. Vrach. 2021;32(10):25-27. (in Russ.) doi: 10.29296/25877305-2021-10-04@@ Успенский Ю. П., Фоминых Ю. А., Гнутов А. А. Поражения полости рта при воспалительных заболеваниях кишечника. Врач. 2021;32(10):25-27. Doi: 10.29296/25877305-2021-10-04.
21. Uspenskiy Y.P., Najafova K. N., Fominykh Y. A., et al. Extraintestinal lesions in inflammatory bowel diseases: focus on the hepatobiliary system. Pharmateca. 2021;28(2):36-42. (in Russ.) doi: 10.18565/pharmateca.2021.2.36-42@@ Успенский Ю. П., Наджафова К. Н., Фоминых Ю. А., Древаль Р. О., Иванов С. В., Шотик А. В., Филиппова В. Н. Экстраинтестинальные поражения при воспалительных заболеваниях кишечника: фокус на гепатобилиарную систему. Фарматека. 2021;28(2):36-42. doi: 10.18565/pharmateca.2021.2.36-42
22. Vavricka S.R., Rogler G., Gantenbein C., et al. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2015;21(8):1794-1800. doi: 10.1097/MIB.0000000000000429
23. Greuter T., Bertoldo F., Rechner R., et al. Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation and anti-TNF Treatment. J Pediatr Gastroenterol Nutr. 2017;65(2):200-206. doi: 10.1097/MPG.0000000000001455
24. Smale S., Natt R. S., Orchard T. R., et al. Inflammatory bowel disease andspondylarthropathy. Arthritis Rheum. 2001;44:2728-2736. doi: 10.1002/1529-0131(200112)44:12<2728:: aid-art459>3.0.co;2-8
25. Orchard T.R., Wordsworth B. P., Jewell D. P. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387-391. doi: 10.1136/gut.42.3.387
26. Fornaciari G., Salvarani C., Beltrami M., et al. Muscoloskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol. 2001;15(6):399-403. doi: 10.1155/2001/612531
27. Su C.G., Judge T. A., Lichtenstein G. R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:307-327. doi: 10.1016/s0889-8553(01)00019-x
28. Veloso F.T., Carvalho J., Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23(1):29-34. doi: 10.1097/00004836-199607000-00009
29. Bernstein C.N., Blanchard J. F., Rawsthorne P., et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a populationbased study. Am J Gastroenterol. 2001;96(4):1116-1122. doi: 10.1111/j.1572-0241.2001.03756.x
30. Braun J., Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol. 1996;8(4):275-287. doi: 10.1097/00002281-199607000-00003
31. Shchukina O.B., Ivanov S. V., Shotik A. V. Practical recommendations for therapists on the diagnosis and treatment of ulcerative colitis. University Therapeutic Journal. 2021;1:58-70. (in Russ.)@@ Щукина О. Б. Иванов С. В., Шотик А. В. Практические рекомендации для терапевтов по диагностике и лечению язвенного колита. University Therapeutic Journal. 2021;1:58-70.
32. Shchukina O.B., Ivanov S. V., Shotik A. V. Practical recommendations for therapists on the diagnosis and treatment of Crohn’s disease. University Therapeutic Journal. 2021;1:71-85. (in Russ.)@@ Щукина О. Б. Иванов С. В., Шотик А. В. Практические рекомендации для терапевтов по диагностике и лечению болезни Крона. Университетский терапевтический вестник. 2021;1:71-85.
33. Lakatos P.L., Lakatos L., Kiss L. S., et al. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion. 2012;86 Suppl 1:28-35. doi: 10.1159/000341950
34. Takeuchi K., Smale S., Premchand P., et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4(2):196-202. doi: 10.1016/s1542-3565(05)00980-8
35. Clegg D.O., Reda D. J., Abdellatif M.Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999;42(11):2325-9. doi: 10.1002/1529-0131(199911)42:11<2325:: AID-ANR10>3.0.CO;2-C
36. Clegg D.O., Reda D. J., Weisman M. H., et al.Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39:2004-12. 1996;39(12):2004-12. Doi: 10.1002/art.1780391209
37. Baraliakos X., Braun J. Biologic therapies for spondyloarthritis: What is new? Curr Rheumatol Rep. 2012;14(5):422-7. doi: 10.1007/s11926-012-0282-2
38. Zhang W., Michalowski C. B., Beloqui A. Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment. Front Bioeng Biotechnol. 2021;9:675194. doi: 10.3389/fbioe.2021.675194
39. Guillo L., D’Amico F., Danese S., Peyrin-Birouletb L. Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review. J Crohns Colitis. 2021;15(7):1236-1243. doi: 10.1093/ecco-jcc/jjaa260
40. Matsumoto S., Matsumoto K., Takaya H., et al. Efficacy of Ustekinumab Against Spondyloarthritis Associated with Crohn’s Disease: A Case Report and Review of the Literature. Open Access Rheumatol. 2020;12:133-137. doi: 10.2147/OARRR.S263259
41. Pugliese D., Daperno M., Fiorino G., et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. Dig Liver Dis. 2019;51(7):972-977. doi: 10.1016/j.dld.2019.03.007
42. Matsumoto S., Mashima H. Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease. Biologics. 2018;12:69-73. doi: 10.2147/BTT.S169326
43. Biemans V.B.C., van der Meulen-de Jong A. E., van der Woude C. J., et al. Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. J Crohns Colitis. 2020;14(1):33-45. doi: 10.1093/ecco-jcc/jjz119
Review
For citations:
Uspenskiy Yu.P., Ivanov S.V., Fominikh Yu.A., Gulunov Z.Kh. Joint syndrome in inflammatory bowel diseases. Experimental and Clinical Gastroenterology. 2022;(2):131-138. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-198-2-131-138
Views:
1034
Email this article 